Purpose We evaluated the clinical efficacy of 0.005% PbXA41, a new phenyl-substituted prostaglandin Fza-isopropyl ester analogue, in primary open angle glaucoma (POAG) and ocular hypertension (OH) patients. We also investigated the effect of PhXA41 on diurnal and noctomal IOP changes in normal volunteers.
Methods 1) A multicentral randomized, double-masked study in which the effkacy on IOP and safety was evaluated for I2 weeks with daily once administration of 0.005% PhXA41 or with daily twice administration of il.! Timolol Maleate as a control drug in thirty five patients with POAG or 2) Sixteen normal volunteers were recruited for the study to evaluate the diurnal and nocturnal change of IOP with daily once administration of 0.005% PhxA41.
Results The mean IOP reduction from baseline after 12 weeks treatments 6.2*2.7 mmHg for PhXA41 and 4.4k2.3 mmHg for Timolol Male&c, respectively. The mean IOP reduction of PhXA41 group was greater than the other one. Major symptoms were only conjunctival hyp=eremia and smarting in both groups. PhXA41 kept reducing IOP with daily once administration either in day and night. or peroperative mitomycin C(MMC) in 100 cases of high risk glaucoma. &&&We prospectwly studied 52 eyes of46 patients treated with MMC (Follow up 15i8.7111) and compared it with a retrospective scrie of48 eyes 01 35 patients treated with 5FU (Follow up 14,3li 11,25m). &w&84% of MMC patients but 46% of 5FU group had a normalized 101' without treatment, and 23% of 5FU vs 5,7 % of MMC patients required systemic glaucoma therapy. Early adverse effects were more'frequently observed with 5FU (cornea 39%, conjonctiva 17% or hypotony 29%) than with MMC (13,46%, 3,85%,13,46% rcspectivly). At last examination, bleb failure requiring additional surgery was more frequent in 5FU group (10%) than MMC (3%), and was mostly associated to anterior chamber factors (i.e. vitreous or lens rclatcd obstruction), rnthcr than cpisclcrnl cclluln~ li~c~owl.o~~g km hypotony was obscrvcd in ill 17.3 % ol the MMC cycs. in this later group 5 of 9 patients had more than 2 lines of best corrected visual acuity reduction. METHODS: pigment rabbits undergoing iXermg surgery were exposed to several intraopemtive treatments: Group 1 (n=S): balanced saline solution; Group 2 (n=5): mitomycin C 0.2 mg/ml: Group 3 (n=S): mitomycin C 0.4 mg/mI. Tissue samples were taken one hour after surgery and included conjunctival and scleral tissue at 00 and 90° area and the adjacent cornea 2 mm from the Iimbus. The biopsies were placed in tissue culture media (trimix media with 2oRo fetal calf serum) and incubated at 370 and PC@ 5%. in a humified atmosphere. Fibmblast outgrowths were measured every 3 days for 12 days: cell morphology was evaluated as well. Repeated-measures analysis of variance was performed each time.
Sieniticance was defined as wO.05.
RI?SULTS:
The average &era1 and conjunctival outgrowth from the. mitomycin-C treated tissues WCR sigaificantly lus than the outgrowth of the eyes treated with BSS, throughout aII the experiment to day 12. The outgrowths from the 90' tissues of mitomycin treated eyes, were signiticaa~y higher than 0" tissues and similar to BSS group. There were no differences behveen eyes treated with mitomycin 0.2 mg/mI and eyes treated with mitomwin 0.4 ma/ml at aw time. tint. The cells arowina out from the mitomycbi C Wated -&as we&abn&al in appcamndz. -The oatgrowths anneal samples were similar in all group. CONCLUSIONS: Intracperative exposure to mitomycin C has an on the local conjunctival and s&d l%mbl&appulation.
effect is similar with mitomycin 0.2 and 0.4 mg/ml. tment-induces abnormal tibmblaab morphology.
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